173 related articles for article (PubMed ID: 11796386)
1. Characterization of mutations in DNA gyrase and topoisomerase IV Involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro.
Reinhardt AK; Bébéar CM; Kobisch M; Kempf I; Gautier-Bouchardon AV
Antimicrob Agents Chemother; 2002 Feb; 46(2):590-3. PubMed ID: 11796386
[TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolone resistance in Mycoplasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topoisomerases on resistance level.
Reinhardt AK; Kempf I; Kobisch M; Gautier-Bouchardon AV
J Antimicrob Chemother; 2002 Oct; 50(4):589-92. PubMed ID: 12356806
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization and typing of enrofloxacin-resistant clinical isolates of Mycoplasma gallisepticum.
Lysnyansky I; Gerchman I; Perk S; Levisohn S
Avian Dis; 2008 Dec; 52(4):685-9. PubMed ID: 19166064
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms involved in quinolone resistance in Mycoplasma mycoides subsp. capri.
Antunes NT; Assunção P; Poveda JB; Tavío MM
Vet J; 2015 Jun; 204(3):327-32. PubMed ID: 25951987
[TBL] [Abstract][Full Text] [Related]
5. Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium.
Yamaguchi Y; Takei M; Kishii R; Yasuda M; Deguchi T
Antimicrob Agents Chemother; 2013 Apr; 57(4):1772-6. PubMed ID: 23357772
[TBL] [Abstract][Full Text] [Related]
6. Discrepancy between minimal inhibitory concentration to enrofloxacin and mutations present in the quinolone-resistance determining regions of Mycoplasma gallisepticum field strains.
Lysnyansky I; Gerchman I; Levisohn S; Mikula I; Feberwee A; Ferguson NM; Noormohammadi AH; Spergser J; Windsor HM
Vet Microbiol; 2012 Nov; 160(1-2):222-6. PubMed ID: 22655973
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of the genes encoding DNA gyrase and topoisomerase IV of Listeria monocytogenes.
Lampidis R; Kostrewa D; Hof H
J Antimicrob Chemother; 2002 Jun; 49(6):917-24. PubMed ID: 12039883
[TBL] [Abstract][Full Text] [Related]
9. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
Pan XS; Hamlyn PJ; Talens-Visconti R; Alovero FL; Manzo RH; Fisher LM
Antimicrob Agents Chemother; 2002 Aug; 46(8):2498-506. PubMed ID: 12121924
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a point mutation in the parC gene of Mycoplasma bovirhinis associated with fluoroquinolone resistance.
Hirose K; Kawasaki Y; Kotani K; Abiko K; Sato H
J Vet Med B Infect Dis Vet Public Health; 2004 May; 51(4):169-75. PubMed ID: 15228551
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis.
Onodera Y; Okuda J; Tanaka M; Sato K
Antimicrob Agents Chemother; 2002 Jun; 46(6):1800-4. PubMed ID: 12019093
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.
Ince D; Zhang X; Silver LC; Hooper DC
Antimicrob Agents Chemother; 2002 Nov; 46(11):3370-80. PubMed ID: 12384338
[TBL] [Abstract][Full Text] [Related]
13. Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.
Oizumi N; Kawabata S; Hirao M; Watanabe K; Okuno S; Fujiwara T; Kikuchi M
J Infect Chemother; 2001 Sep; 7(3):191-4. PubMed ID: 11810583
[TBL] [Abstract][Full Text] [Related]
14. Resistance mechanisms against quinolones in Mycoplasma capricolum subsp. capricolum.
Tatay-Dualde J; Prats-van der Ham M; de la Fe C; Paterna A; Sánchez A; Corrales JC; Contreras A; Gómez-Martin Á
Vet J; 2017 May; 223():1-4. PubMed ID: 28671064
[TBL] [Abstract][Full Text] [Related]
15. DNA gyrase and topoisomerase IV mutations in an in vitro fluoroquinolone-resistant Coxiella burnetii strain.
Vranakis I; Sandalakis V; Chochlakis D; Tselentis Y; Psaroulaki A
Microb Drug Resist; 2010 Jun; 16(2):111-7. PubMed ID: 20438350
[TBL] [Abstract][Full Text] [Related]
16. Contribution of Type II Topoisomerase Mutations to Fluoroquinolone Resistance in Enterococcus faecium from Japanese Clinical Setting.
Urushibara N; Suzaki K; Kawaguchiya M; Aung MS; Shinagawa M; Takahashi S; Kobayashi N
Microb Drug Resist; 2018; 24(1):1-7. PubMed ID: 28504916
[TBL] [Abstract][Full Text] [Related]
17. Quinolone resistance mechanisms in pneumococci.
Eliopoulos GM
Clin Infect Dis; 2004 May; 38 Suppl 4():S350-6. PubMed ID: 15127369
[TBL] [Abstract][Full Text] [Related]
18. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of action of and resistance to quinolones.
Bearden DT; Danziger LH
Pharmacotherapy; 2001 Oct; 21(10 Pt 2):224S-232S. PubMed ID: 11642689
[TBL] [Abstract][Full Text] [Related]
20. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa.
Kugelberg E; Löfmark S; Wretlind B; Andersson DI
J Antimicrob Chemother; 2005 Jan; 55(1):22-30. PubMed ID: 15574475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
